Success Story: EB-1A Approval for a Medicinal Chemistry Researcher After Successfully Overcoming an RFE
Client’s Testimonial:
"Thanks again for the tremendous support during the process of filing my EB1A. You guys are truly fantastic.”
On July 1st, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellow in the Field of Medicinal Chemistry (Approval Notice).
General Field: Medicinal Chemistry
Country of Origin: Postdoctoral Fellow
Country of Residence at the Time of Filing: India
Approval Notice Date: July 1st, 2026
Processing Time: 4 months, 5 days (Premium Processing Requested)
Case Summary:
North America Immigration Law Group is pleased to share the approval of an I-140 EB-1A petition for a medicinal chemistry researcher from India. Prepared under the Dhanasar framework, the petition demonstrated the substantial merit and national importance of the proposed endeavor, the client’s strong positioning to advance it, and the benefit of waiving the job offer and labor certification requirements. At the time of filing, the client held a Ph.D. in medicinal chemistry and was conducting research in antimicrobial resistance and small-molecule drug design.
The client’s research focuses on designing green synthetic protocols for small molecules with antimicrobial and anticancer activity, including work on various classes of bioactive compounds and synthetic methodologies. The petition emphasized that these contributions address critical national and global health needs, including combating antimicrobial resistance and advancing drug discovery, which are priorities in U.S. biomedical research and public health.
The client’s record included 15 peer-reviewed journal articles (8 first-authored), 2 first-authored book chapters, at least 10 peer reviews for top journals, and 631 citations. His work has been published in well-regarded, high-impact scientific journals.
Independent researchers worldwide have relied on the client’s discoveries in studies related to various areas of medicinal chemistry and synthetic methodology. These citations demonstrate that his work has practical significance, advancing drug design, synthetic methodology, and antimicrobial development across multiple countries and institutions.
The petition included 2 recommendation letters from internationally recognized experts, highlighting the client’s originality, sustained contributions, and influence in medicinal chemistry. One expert emphasized:
“Collectively, his work has important implications for the development of next-generation antibiotics, strengthening U.S. healthcare, and addressing the growing challenge of bacterial resistance.”
The I-140 EB-1A petition was filed on February 26th, 2026, with premium processing requested at the time of filing, and approved on July 1st, 2026, after an RFE. This approval reflects the client’s extraordinary ability, citation impact, expert recognition, and national importance of his work in medicinal chemistry and drug discovery.
We congratulate the client on this EB-1A approval and look forward to his continued contributions to antimicrobial and anticancer drug research in the United States.